ASCO: Lisocabtagene maraleucel (liso-cel)

Lisocabtagene maraleucel (liso-cel) for treatment of second-line (2L) transplant noneligible (TNE) relapsed/refractory (R/R) aggressive large B-cell nonHodgkin lymphoma (NHL)

Abstract No : 8040

Indication : Non-Hodgkin's Lymphoma (aggressive)

Intervention : Lisocabtagene maraleucel

Company : Juno Therapeutics, a Bristol-Myers Squibb company

Technology : CAR T Cell therapy


At data cutoff, 25 pts had LD followed by liso-cel infusion. Pt characteristics are summarized in the Table. Overall, 48% (n = 12) had high tumor burden and 48% were primary refractory. 18/25 (72%) pts had grade ≥3 treatment-emergent AEs, 40% of which were cytopenias. No grade 5 AEs occurred within the first 30 days after liso-cel. Five pts (20%) had cytokine release syndrome (CRS) and 3 (12%) had neurological events (NEs). No grade 3/4 CRS was observed; 2 pts (8%) had grade 3/4 NEs. Five pts (20%) received tocilizumab and/or dexamethasone for CRS/NEs. At a median follow-up of 3.5 mo, the ORR was 80% (95% CI, 59–93; n = 20); 48% of pts (n = 12) achieved CR.


These interim data suggest that elderly and/or comorbid pts with R/R aggressive large B-cell NHL, who are not eligible for high-dose chemotherapy and HSCT, can receive 2L liso-cel with similar safety and efficacy to 3L+ pts as previously reported (Abramson, ASH 2019 #241). Updated data with longer follow-up will be presented.


Early results in second line, transplant ineligible setting were highly encouraging with 80% ORR and complete response in almost half of the patients; Liso-cel has already submitted the BLA with PDUFA in August.

Refer to Non-Hodgkin's Lymphoma Market report for detailed Insights.